Karli Hochstatter, PhD, MPH, joins Columbia University’s SIG as a T32 Postdoctoral Research Fellow in the HIV, Substance Abuse, and Criminal Justice T32 Fellowship Program. Dr. Hochstatter comes from the University of Wisconsin Madison, where her research focuses on preventing HIV and hepatitis C virus transmission and improving screening and treatment uptake among populations disproportionately burdened by substance use disorders, with a special focus on people who inject drugs and criminal justice-involved adults.
Dr. Hochstatter completed her PhD in Population Health Sciences with a minor in Criminal Justice Health (2019), Master of Public Health (2015), and Bachelor of Science (2013) degrees at the University of Wisconsin School of Medicine and Public Health. While at UW-Madison, she also served as an assistant for the UW Cooperative Extension Opioid Task Force, disseminating evidence-based opioid overdose prevention interventions to community coalitions across Wisconsin. Dr. Hochstatter is also a scholar in the Criminal Justice Research Training Program on Substance Use, HIV, and Comorbidities at Brown University.
Dr. Hochstatter has worked on several NIDA-funded research projects that address the intersecting epidemics of injection drug use and infectious diseases, particularly hepatitis C virus and HIV. Her dissertation research focused on using mobile health technology to improve hepatitis C and HIV-related outcomes and reduce opioid overdose death among people with opioid use disorder, as well as computer-tailored risk-reduction interventions that improve the health of people who inject drugs when implemented in harm reduction settings. She also served as project manager for a longitudinal cohort study of HIV-positive persons transitioning from prison to community-based care. In addition to this work, Dr. Hochstatter is currently working on using Global Hepatitis Outbreak Surveillance Technology, a tool recently developed by the CDC, to characterize hepatitis C transmission clusters among social networks of people who inject drugs and incarcerated persons.
While at Columbia, Dr. Hochstatter will continue to develop, implement, and disseminate innovative strategies to prevent the transmission of HIV and hepatitis C virus among people with substance use disorders.